Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Prilosec OTC Heats Up Heartburn Sector; Competitors Set Sights On Launch

This article was originally published in The Tan Sheet

Executive Summary

Pfizer has initiated a competitive advertising campaign against Prilosec as Procter & Gamble gears up to introduce the OTC version of the proton pump inhibitor this quarter

You may also be interested in...



Zantac 75 Ad Comparison to Prilosec OTC Needs Revision, NAD Concludes

Ad claims for Pfizer's Zantac 75 that compare the H2 antagonist to Procter & Gamble's Prilosec OTC should be modified so consumers understand the heartburn remedies have different indications, the National Advertising Division of the Council for Better Business Bureaus concludes following a recent inquiry

Zantac 75 Ad Comparison to Prilosec OTC Needs Revision, NAD Concludes

Ad claims for Pfizer's Zantac 75 that compare the H2 antagonist to Procter & Gamble's Prilosec OTC should be modified so consumers understand the heartburn remedies have different indications, the National Advertising Division of the Council for Better Business Bureaus concludes following a recent inquiry

Zantac 75 Ad Comparison to Prilosec OTC Needs Revision, NAD Concludes

Ad claims for Pfizer's Zantac 75 that compare the H2 antagonist to Procter & Gamble's Prilosec OTC should be modified so consumers understand the heartburn remedies have different indications, the National Advertising Division of the Council for Better Business Bureaus concludes following a recent inquiry

Related Content

Topics

Latest News
UsernamePublicRestriction

Register

PS095775

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel